Drug Profile
KappaMab - HaemaLogiX
Alternative Names: IST-1097; MDX-1097; MDX-1097 (kappa)Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Immune System Therapeutics; Medarex
- Developer HaemaLogiX
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Myeloma-associated membrane antigen KMA modulators; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple myeloma
Most Recent Events
- 01 Sep 2023 HaemaLogiX in collaboration with Celgene complete a phase IIb trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (ACTRN12616001164482p)
- 29 Jun 2023 Final efficacy data from a phase IIb trial in Myeloma released by HaemaLogiX
- 29 Jun 2023 Efficacy data from a phase IIb trial in Multiple myeloma released by HaemaLogiX